Table 1.
Patient characteristics (PHANTOM)
| n = 55 | |
|---|---|
| Age, yr | 61 ± 10.3 |
| Sex, female, % | 67 |
| Body mass index, kg/m2 | 30.1 ± 6.4 |
| Race, % | |
| White | 80 |
| African American | 7 |
| Other | 13 |
| PAH etiology, % | |
| Idiopathic/heritable | 49 |
| Connective tissue disease | 24 |
| Other | 27 |
| PAH medications, % | |
| Only oral | 67 |
| Inhaled ± oral | 11 |
| Parenteral prostacyclin analog ± oral | 22 |
| WHO functional class, % | |
| I | 7 |
| II | 64 |
| III | 29 |
| emPHasis-10 | 19 ± 9 |
| SF-36–MCS | 55 ± 7 |
| SF-36–PCS | 37 ± 8 |
| 6-minute walk distance, m | 424 ± 113 |
| TAPSE, cm | 2.2 (1.9–2.6) |
| Right ventricular dysfunction, % | |
| None | 11 |
| Mild | 42 |
| Moderate | 36 |
| Severe | 11 |
| Accelerometry variables (per day) | |
| Vector magnitude counts | 355,600 ± 158,400 |
| Step counts | 3,860 ± 2,830 |
| Sedentary, min | 610 (508–680) |
| Light activity, min | 165 (131–190) |
| Moderate activity, min | 8 (2–13) |
Definition of abbreviations: MCS = mental component score; PAH = pulmonary arterial hypertension; PCS = physical component score; PHANTOM = Pulmonary Hypertension and Anastrozole; SF-36 = Short form-36; TAPSE = tricuspid annular plane systolic excursion; WHO = World Health Organization.
Data are summarized as mean ± SD or median (interquartile range).